Showing results (61-70 of 90) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2014
Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study GroupThomas Schroeder, Elena Rachlis, Gesine Bug, et al.
Leukemia|February 18, 2021
Selective elimination of immunosuppressive T cells in patients with multiple myelomaMohamed H S Awwad, Abdelrahman Mahmoud, Heiko Bruns, et al.
European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.
Bone Marrow Transplantation|November 12, 2024
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMatjaz Sever, Joanna Drozd-Sokolowska, Luuk Gras, et al.
Bone Marrow Transplantation|December 5, 2024
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myelomaNora Grieb, Alexander Oeser, Maximilian Ferle, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Cancers|August 23, 2020
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD AssessmentKatharina Kriegsmann, Michael Hundemer, Nicole Hofmeister-Mielke, et al.
European Journal of Haematology|April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT studyNico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Pageof 9